Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
Best tumor response and overall response rate (ORR) by disease site (n... | Download Table
Iovance Biotherapeutics: The Frontier Of Novel Cancer Treatment (NASDAQ:IOVA) | Seeking Alpha
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial | PLOS ONE
Analysis of duration of response in oncology trials. | Semantic Scholar
Clinical Trial Endpoints for Oncology Studies
Best Overall Response and Time to Response | Download Table
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text
Four Big Trials at ASCO Yield Practice-Changing Data
Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text
Efficacy endpoints in Oncology
Study Results | ZYNLONTA® (loncastuximab tesirine-lpyl) Patient Site
Objective response rate assessment in oncology: Current situation and future expectations
Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial | PLOS ONE
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer - touchONCOLOGY
Starting with higher-dose prednisone boosts 1-year renal response in lupus nephritis
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
Dara-KRd and tandem ASCT for patients with high-risk NDMM: Results of the IFM-2018-04 trial
Frontiers | Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study